Announcing Iovance Biotherapeutics (Formerly Lion Biotechnologies)

ADVANCING IMMUNO-ONCOLOGY
CLINICAL TRIALS

IOVANCE is conducting three Phase 2 clinical trials to assess the efficacy and safety of autologous Tumor Infiltrating Lymphocytes for treatment of patients with Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck and Cervical Cancer.

C-144-01 is a multicenter clinical trial now recruiting patients with Metastatic Melanoma at various sites in the US.

C-145-03 is a multicenter clinical trial now recruiting patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at various sites in the US.

C-145-04 is a multicenter clinical trial now recruiting patients with Cervical Carcinoma at various sites in the US.

Learn
Latest News

Sign up for email alerts

Be the first to receive breaking news

Join